Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG MIX 70 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG MIX 70 30.
HUMALOG MIX 75/25 vs NOVOLOG MIX 70/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphasic insulin analog combining rapid-acting insulin lispro (25%) and intermediate-acting insulin lispro protamine suspension (75%). Insulin lispro lowers blood glucose by binding to insulin receptors, facilitating cellular glucose uptake, inhibiting hepatic gluconeogenesis, and promoting glycogenesis and lipogenesis.
Biphasic insulin analog combining rapid-acting insulin aspart and intermediate-acting protamine-crystallized insulin aspart, which lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production.
Subcutaneous injection: 75% insulin lispro protamine suspension and 25% insulin lispro solution. Dose individualized based on glycemic goals and prior insulin regimen. Typical total daily dose: 0.5-1 unit/kg/day divided into two doses (pre-breakfast and pre-dinner).
Subcutaneous injection only. Typical total daily insulin dose ranges from 0.5 to 1.0 units/kg/day divided into two or three injections. Administer twice daily, with each dose given within 15 minutes before meals. Dose individualization based on glycemic targets and previous insulin regimen is required.
None Documented
None Documented
Insulin lispro: 0.5-1 hour; protamine-bound fraction prolongs absorption, resulting in a biphasic profile with an effective half-life of 2-4 hours for the 75% NPL component.
Insulin aspart (free component): ~1-2 hours; protamine-crystallized component: ~8-10 hours. Clinical context: Duration of action up to 24 hours due to the intermediate-acting component.
Renal: 60-80% as unchanged drug following subcutaneous absorption; the remaining fraction undergoes hepatic metabolism and biliary/fecal excretion.
Renal: 30-80% of dose excreted unchanged in urine for insulin aspart; for protamine-crystallized component, metabolism and renal elimination also occur. Biliary/fecal: Minor.
Category C
Category C
Insulin Analog
Insulin Analog